"Road map for interactions" sets new standards of ethics
This article was originally published in Clinica
AdvaMed's board of directors has unanimously approved a new voluntary code of ethics on interactions with healthcare professionals that could spark a profound shift in sales and marketing practices when it goes into effect on September 1.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.